Q2
APMD — Q2 2026 Financial Report Analysis
Apnimed's $125.9M Q2 profit came from $142.5M of one-time gains on unwinding its Shionogi ties. Without them it lost money, with $172.8M of cash plus $200.4M of IPO proceeds ahead of a Feb 28, 2027 FDA decision on Oxnimbi.